Crossmark Global Holdings Inc. Raises Stock Holdings in Humana Inc. (NYSE:HUM)

Crossmark Global Holdings Inc. lifted its holdings in Humana Inc. (NYSE:HUM) by 11.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,068 shares of the insurance provider’s stock after purchasing an additional 915 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Humana were worth $2,300,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. International Assets Investment Management LLC boosted its holdings in shares of Humana by 261,025.1% in the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after purchasing an additional 738,701 shares during the period. FMR LLC lifted its position in Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after buying an additional 643,291 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Humana by 55.6% during the third quarter. Thrivent Financial for Lutherans now owns 600,317 shares of the insurance provider’s stock worth $190,145,000 after buying an additional 214,535 shares during the period. Pzena Investment Management LLC increased its position in Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after acquiring an additional 187,903 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC purchased a new stake in shares of Humana in the third quarter valued at $50,102,000. Institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on HUM shares. KeyCorp assumed coverage on shares of Humana in a research note on Friday, October 11th. They set a “sector weight” rating for the company. Barclays boosted their target price on Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday. Morgan Stanley increased their price target on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Leerink Partners cut Humana from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $400.00 to $250.00 in a report on Wednesday, October 2nd. Finally, Leerink Partnrs lowered Humana from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Twenty analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $302.80.

Humana Price Performance

NYSE HUM opened at $293.22 on Friday. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $411.80. The firm’s fifty day simple moving average is $273.81 and its two-hundred day simple moving average is $305.88. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $35.31 billion, a P/E ratio of 25.97, a P/E/G ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUM) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Analysts forecast that Humana Inc. will post 16.11 EPS for the current fiscal year.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.